Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...
Benzinga.com23d
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Enobosarm + semaglutide reduced lean mass loss by 71% ... The study evaluates the safety and efficacy of enobosarm 3mg and enobosarm 6mg, compared to placebo in 168 older patients, greater than ...
Yahoo Finance15d
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
The enobosarm 3mg + semaglutide was the best dose with a >99% mean relative reduction in loss of lean mass (p <0.001). Enobosarm 6mg + semaglutide dose was not better than the Enobosarm 3mg ...
pharmaphorum4d
High-dose semaglutide ramps up weight loss, says Novo
The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.